Although there are marked differences in the upstream regulators of ErbB2 and myosin heavy chain, many downstream effector molecules are common and can be targeted by small-molecule inhibitors (designed initially to treat several types of cancer) to block cardiac hypertrophy. This evidence concerns the gene ERBB2 and cancer.